The UromigosLive 2025 meeting presents #UromigosShorts videos on GU Oncology topics. The videos with the most views win a prize at #UromigosLive November 7-8th in Nashville, TN. Below, Dr. Amanda Nizam discusses: Enfortumab Vedotin Toxicity.

@DrSpratticus giving the Felix Feng Legacy Lecture Felix’s impact on patients is mind boggling. And will continue for decades, at minimum Amazingly, his impact on team science and mentoring in #ProstateCancer may be even larger!

📋Recommendations for AE management & procedural best practices for IDRS 🥨🥨🥨 👀OPEN ACCESS, read it: https://t.co/QLzCD0xcZt 👥Collaborative review with 🔝 co-authors: @BenjaminPradere @DrShariat @BerUrologia @spsutkaMD among others!

Great work done @UroCancerMD @UrogerliMD @SpiessPhilippe @BrynLauner @VikramNarayan @siadaneshmand @bkonety to validate the CHAI (Computational Histology Artificial Intelligence) model for risk stratification of patients with Ta HG #NMIBC in a multicenter cohort: ☑️CHAI

‼️ A point lost on many Personalized Medicine proponents - if the interaction effect is weak for the biomarker you are purporting to use to personalize treatment, the absolute loss is worse for the patient than just assuming the average treatment effect applies to every patient

A few more subjectively selected #ESMO25 takeaways for #ProstateCancer @myESMO @urotoday @oncodaily @Uroweb 1️⃣ EMBARK, LBA87, @laconss In high-risk biochemically recurrent, non-metastatic PCa (PSA-DT ≤9 mo), Enzalutamide + ADT improved MFS and OS. Does this set a new SoC?

Recommend listening to this yet another amazing @Uromigos podcast @tompowles1 @brian_rini #MattGalsky Awesome discussion on the DV-toripalimab data from @myESMO #ESMO25, nuances, how it fits with Her-2 expression & in the EV-P landscape.

Missed out on #ESMO25? Stay tuned for upcoming congress highlights that fit around your busy schedule. For now, catch up with the latest insights on improving the patient experience in #bladdercancer care from @JoshMeeks and @DrFelixGuerrero #MedX https://t.co/5vhVgHgZqv

Some selected key #ESMO25 #BladderCancer Highlights + follow-up questions we need to address: 1️⃣ Perioperative EV + Pembro presented by Christof Vulsteke ✅ Big efficacy: with 57% pCR, EFS HR 0.4, OS HR 0.5, perioperative EV/Pembro sets a new bar in #MIBC💥 and it looks like we

🚨 In this episode Christof Vulsteke joins Brian and Tom to discuss his practice-changing data on neoadjuvant EVP in MIBC.  🎙️ GU Oncology Now:  https://t.co/tq6ij4QLoO    🍎 Apple Podcasts:  https://t.co/tq6ij4QLoO   🎧Spotify:  https://t.co/Zm9En8bbMK

🚨More from ESMO 2025. In this episode Scott Tagawa discusses his ESMO Presidential presentation on Lu-PSMA-617 in patients with mHSPC.  🎙️ GU Oncology Now: https://t.co/OYGGB9OKaL  🍎 Apple Podcasts:    https://t.co/kj0GIbMGsR 🎧Spotify: https://t.co/bg8WeZ5BRL

Indeed time to question #RadicalCystectomy with 57% pCR post neoadj. EV/P #ESMO25 Few questions remain🔹Who can safely skip RC (ctDNA? yet ctDNA–≠risk-free)🔹Maintenance vs observation🔹Could chronic syst. Tx harm QoL more than surgery?@oncodaily @Uroweb @daviesbj @AlisonBirtle

#ESMO25 EMBARK Enza+ADT: MFS/OS ⬆️ in HR BCR #ProstateCancer Does this set a new SoC? ❓EMBARK used historic imaging/no #PSMA, limiting true stage Dx ❓Earlier local treatment partially missed ➡️Modern staging needs to reshape who truly benefits @oncodaily @urotoday @laconss

Successful biomarker guided strategy: IMvigor011 results presented @tompowles1 #ESMO25 ctDNA-guided adjuvant #atezolizumab after cystectomy in #MIBC ➡️ DFS HR 0.64 ➡️ OS HR 0.59 vs placebo in ctDNA⁺ pts ➡️ ctDNA⁻ pts w/o: 2-yr OS of 97% #MRD #BladderCancer @oncodaily @urotoday

Results discussed by @AzadOncology: ✅ biomarkers needed for patient selection ✅ do all patients need 6 cycles? ✅ Tox of early RLT needs to be considered especially as side effects were numerically higher with Lu#PSMA #ProstateCancer #ESMO25 @oncodaily @urotoday

PSMAddition results presented #ESMO25 by @DrScottTagawa Adding [¹⁷⁷Lu]-#PSMA-617 to ADT+ARPI significantly improved rPFS in mHSPC (HR 0.72; p = 0.002) Consistent benefit across subgroups, HRQoL maintained, OS immature/not significant #ProstateCancer @oncodaily @urotoday

Finally, we have large RCTs to debate, discuss, and comb over and not just single arm trials. The amount we will learn about NMIBC from these cohorts will be vast.

Excellent discussion by @DrRosenbergMSK Open questions: 1️⃣ neoadjuvant vs adjuvant contribution 2️⃣ need for post-op therapy in pCR/ctDNA-neg pts 3️⃣ can ctDNA/pCR guide individual treatment decisions? 4️⃣ way to potential bladder-sparing approach? @oncodaily #ESMO25 #urotoday

KEYNOTE-905 results presented @ #ESMO25 by Christof Vulsteke: Perioperative EV/Pembro sets a new bar in #MIBC💥 Impressive outcomes: EFS HR 0.4, OS HR 0.5, pCR 57% #BladderCancer @oncodaily @urotoday #UroOnc #ADC

#ESMO25 With no significant MFS ⬆️ with enza+ADT in #Enzarad, benefit was seen in #ProstateCancer patients with N+/pelvic radiation. Question now: is there a true benefit for these patients + can we define criteria to determine a net clinical benefit? @DrPaulNguyen @oncodaily